Status:
WITHDRAWN
Treatment of Patients With Donor Lymphocytes Sensitized by Antigens Expressed by the Host
Lead Sponsor:
Hadassah Medical Organization
Conditions:
Hematological Malignancy
Neoplasm Metastasis
Eligibility:
All Genders
Phase:
PHASE2
Brief Summary
Allogeneic stem cell transplantation is the only effective treatment to patients resistant to conventional chemotherapy. Donor lymphocytes infusion (DLI) serve as a routine treatment of choice for pat...
Eligibility Criteria
Inclusion
- Patients with hematologic malignancy or metastatic solid tumor relapsing following allogeneic bone marrow or blood stem cell transplantation (alloBMT) or non-myeloablative stem cell transplantation resistant to DLI with no GVHD when taken off anti-GVHD prophylaxis.
- Patients with documented chimerism to confirm induction of host-vs-graft transplantation tolerance.
Exclusion
- Patients not consenting to participate in the study, or minors without approved parental consent.
- Patients with other diseases or complications that may limit their life span other than their basic disease.
- Pregnant or lactating women.
- Non-compliant patients or patients with poor performance status with life expectancy, e.g. 6 weeks.
Key Trial Info
Start Date :
August 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00149032
Start Date
August 1 2001
Last Update
April 8 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hadassah Medical Organization
Jerusalem, Israel, 91120